Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells

Circulation

Volumn 112, Issue 5, 2005, Pages 720-726

  Sen Banerjee, Sucharita ^a,b   Mir, Samy ^a   Lin, Zhiyong ^a   Hamik, Anne ^a   Atkins, G Brandon ^a   Das, Hiranmoy ^a   Banerjee, Pallab ^a   Kumar, Ajay ^a   Jain, Mukesh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Endothelium; Nitric oxide synthase; Transcription; Vessels

Indexed keywords

COMPACTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KRUPPEL LIKE FACTOR 2; MESSENGER RNA; MEVALONIC ACID; MEVINOLIN; MYOCYTE ENHANCER FACTOR 2; PRAVASTATIN; RHO FACTOR; SIMVASTATIN; SMALL INTERFERING RNA; THROMBOMODULIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; ENDOTHELIUM CELL; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; WESTERN BLOTTING;

5' UNTRANSLATED REGIONS; BASE SEQUENCE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NITRIC OXIDE SYNTHASE TYPE III; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; THROMBOMODULIN; TRANSFECTION; UMBILICAL VEINS;

EID: 23244457776     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.525774     Document Type: Article

References (33)

1. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109:II-18-II-26.
2. Liao JK, Laufs U. Pleiotropic effects of statins. Anna Rev Pharmacol Toxicol. 2005;45:89-118.
3. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med. 2000;32:164-176.
4. Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb. 2004;11:62-72.
5. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
6. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266-24271.
7. Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, Miyamori I. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003;23:512-517.
8. Mehta JL, Li DY, Chen HJ, Joseph J, Romeo F. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun. 2001;289:857-861.
9. Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis. 2003;14:575-585.
10. Vita JA, Yeung AC, Winniford M, Hodgson JM, Treasure CB, Klein JL, Werns S, Kern M, Plotkin D, Shih WJ, Mitchel Y, Ganz P. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 2000;102:846-851.
11. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109:11-27-11-33.
12. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation. 2004;109:II-34-II-41.
13. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981;78:2249-2252.
14. Esmon CT. Coagulation and inflammation. J Endotoxin Res. 2003;9:192-198.
15. Esmon CT. Inflammation and thrombosis. J Thromb Haemost. 2003;1:1343-1348.
16. Casey PJ. Protein lipidation in cell signaling. Science. 1995;268:221-225.
17. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241-269.
18. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
19. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
20. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110:285-288.
21. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:58-63.
22. SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DI. Luscinskas FW, Michel TM: Gimbrone MA Jr, Garcia-Cardena G, Jain MK. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004;199:1305-1315.
23. Lin Z, Kumar A, SenBanerjee S, Staniszewski K, Parmar K, Vaughan DE, Gimbrone MA Jr, Balasubramanian V, Garcia-Cardena G, Jain MK. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res. 2005;96:e48-e57.
24. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res. 2002;91:143-150.
25. Gonzalez E, Nagiel A, Lin AJ, Golan DE, Michel T. Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling pathways in endothelial cells. J Biol Chem. 2004;279:40659-40669.
26. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-2719.
27. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, Ramirez JR, Friedman S, Bernabeu C. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood. 2002;100:4001-4010.
28. Wang L, Fan C, Topol SE, Topol EJ, Wang Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003;302:1578-1581.
29. Lin Q, Lu J, Yanagisawa H, Webb R, Lyons GE, Richardson JA, Olson EN. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development. 1998;125:4565-4574.
30. Hayashi M, Kim SW, Imanaka-Yoshida K, Yoshida T, Abel ED, Eliceiri B, Yang Y, Ulevitch RJ, Lee JD. Targeted deletion of BMKI/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest. 2004;113:1138-1148.
31. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Nature. 2001;411:494-498.
32. Vita JA, Gokce N, Duffy SJ, Kahn D, Tomasian D, Palmisano J, Thomas S, Holbrook M, Keaney JF Jr. Effect of atorvastatin on endothelium-dependent vasodilation in patients with coronary artery disease. Am J Cardiol. 2003;91:857-860.
33. Laufs U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res. 2000;87:526-528.